Although this finding did not concur with the cost-effectiveness analyses conducted in other countries showing a favorable cost-effectiveness of nivolumab versus docetaxel in previously treated advanced NSCLC patients regardless of PD-L1 expression (13, 14), different perspectives, trial source used for analysis, and approach to modeling used between these studies have to be highlighted that may explain the inconsistency. Here, CD274 is linked to non-small cell lung carcinoma.